Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge

Hyeree Choi(The Wistar Institute), Kar Muthumani(The Wistar Institute), David B. Weiner(The Wistar Institute), Piyush Borole(The Wistar Institute), Charles C. Reed(Inovio Pharmaceuticals (United States)), Sangya Agarwal(Amgen (United States)), Gayathri Gulendran(University of Pennsylvania), Kenneth E. Ugen(University of South Florida), Emma L. Reuschel(The Wistar Institute), Gary Kobinger(Global Affairs Canada), J Joseph Kim(Inovio Pharmaceuticals (United States)), Kate E. Broderick(Inovio Pharmaceuticals (United States)), Stephanie Ramos(Inovio Pharmaceuticals (United States)), Sagar B. Kudchodkar(The Wistar Institute), Lucas Van Gorder(University of Pennsylvania), Kanika Asija(The Wistar Institute), Don L. Siegel(University of Pennsylvania)
Human Vaccines & Immunotherapeutics
December 4, 2019
Cited by 13


Related Papers